Postremission Outcomes at 4 Years Among Children With and Without Down Syndrome
| . | N . | DS Outcome . | %CI95 . | N . | No DS Outcome . | %CI95 . | P Value . | |
|---|---|---|---|---|---|---|---|---|
| Postremission* | ||||||||
| RFS | 87 | 86% | (58-97) | 730 | 57% | (49-65) | .0002 | |
| DFS | 87 | 81% | (52-94) | 730 | 56% | (49-63) | .0002 | |
| Chemotherapy | 64 | 89% | (38-99) | 232 | 54% | (37-70) | .0001 | |
| Allogeneic BMT† | 3 | 33% | (6-79) | 153 | 71% | (61-80) | .17 | |
| Autologous BMT† | 6 | 67% | (30-90) | 199 | 56% | (48-64) | .49 |
| . | N . | DS Outcome . | %CI95 . | N . | No DS Outcome . | %CI95 . | P Value . | |
|---|---|---|---|---|---|---|---|---|
| Postremission* | ||||||||
| RFS | 87 | 86% | (58-97) | 730 | 57% | (49-65) | .0002 | |
| DFS | 87 | 81% | (52-94) | 730 | 56% | (49-63) | .0002 | |
| Chemotherapy | 64 | 89% | (38-99) | 232 | 54% | (37-70) | .0001 | |
| Allogeneic BMT† | 3 | 33% | (6-79) | 153 | 71% | (61-80) | .17 | |
| Autologous BMT† | 6 | 67% | (30-90) | 199 | 56% | (48-64) | .49 |
*Based on as-treated analysis; excluded are 331 not in remission and 28 event/censored before entry.
Two-year DFS.